Pfizer | PFE - Des Atouts





Des Atouts Changement Date
AbbVie USD 135.12B 1.35B 2026-06
Abbott USD 110.43B 23.72B 2026-03
ALKERMES USD 4.39B 135.05M 2026-06
Amgen USD 95.64B 3.14B 2026-06
AstraZeneca USD 115.83B 1.82B 2026-06
Bayer EUR 107.29B 659M 2026-06
Biogen USD 32.09B 2.6B 2026-06
Bristol-Myers Squibb USD 87.63B 1.16B 2026-06
Coherus Biosciences USD 191.18M 74.84M 2026-06
Drreddys Laboratories INR 579.35B 573.08B 2026-03
Eli Lilly USD 142.28B 25.71B 2026-06
Gilead Sciences USD 49.36B 6.92B 2026-06
GlaxoSmithKline GBP 61.74B 1.13B 2026-06
Glaxosmithkline GBP 62.87B 19.47B 2026-03
J&J USD 201.06B 167M 2026-06
Medtronic USD 91.48B 139M 2025-12
Merck USD 129.8B 1.12B 2026-06
Neurocrine Biosciences USD 5.36B 452.9M 2026-06
Novartis USD 122.03B 3.5B 2026-06
Novartis USD 118.53B 7.58B 2026-03
Pacira USD 1.24B 35.44M 2026-06
Perrigo USD 7.61B 373.8M 2026-06
Pfizer USD 201.13B 6.49B 2026-06
Phibro Animal Health USD 1.45B 39.56M 2026-03
Prestige Brands USD 4.57B 1.07B 2026-06
Regeneron Pharmaceuticals USD 41.73B 861.8M 2026-06
Roche Holding CHF 98.2B 2.5B 2026-06
Sanofi EUR 129.06B 1.04B 2026-06
Sanofi EUR 128.02B 1.22B 2026-03
Vertex Pharmaceuticals USD 27.42B 938.9M 2026-06
Zoetis USD 15.08B 77M 2026-06